Company intelligence / Profile preview

Repertoire Genesis

Ibaraki (Saito district, Osaka-fu), Osaka, Japan

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Repertoire Genesis provides immune repertoire and neo-epitope analysis as a service to academia and pharmaceutical companies to support basic research, biomarker development, and clinical development in cancer, autoimmune and infectious diseases; it does not appear to run its own interventional drug trials but its technologies are used in clinical trials as exploratory or biomarker tools.[1][4][5]

Modalities: Non-pharmacological therapy
Industry: Molecular Diagnostics

Partnerships

Multiple domestic and overseas research institutes including The University of Tokyo Hospital and University of California San Diego (research collaborations using its analysis services)[1][5]

Beyond the preview

Go deeper on Repertoire Genesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Repertoire Genesis.

Explore the full profile